(Press-News.org) Systemic light chain (AL) amyloidosis is a rare and life-threatening disorder characterized by the deposition of misfolded immunoglobulin light chains as insoluble amyloid fibrils in various tissues and organs, leading to progressive structural and functional impairment. Commonly affected sites include the heart, kidneys, liver, gastrointestinal tract, and nervous system, with cardiac involvement being the primary determinant of prognosis. Due to its nonspecific clinical presentation and multisystem nature, AL amyloidosis is often diagnosed at an advanced stage, contributing to high early mortality. This review synthesizes recent advances in the diagnosis, risk stratification, and treatment of AL amyloidosis, highlighting the integration of novel biomarkers, imaging modalities, and targeted therapies that are reshaping clinical management.
Pathogenesis and Risk Factors
AL amyloidosis arises from clonal plasma cell disorders, most commonly monoclonal gammopathy of undetermined significance or multiple myeloma. These cells produce unstable light chains that misfold, aggregate into β-sheet-rich fibrils, and deposit in tissues, causing direct cellular toxicity, oxidative stress, and chronic inflammation. Key risk factors include advanced age (median 56 years) and pre-existing plasma cell dyscrasias. Early recognition in high-risk populations is essential for improving outcomes.
Clinical Presentation and Diagnostic Approaches
Clinical manifestations are highly variable and depend on the organs involved. Cardiac amyloidosis presents as heart failure or arrhythmias, whereas renal involvement leads to proteinuria and renal insufficiency. Peripheral neuropathy, hepatomegaly, gastrointestinal dysmotility, and characteristic signs such as macroglossia and periorbital purpura may also occur, though the latter are present in only about 15% of patients.
Diagnosis relies on a combination of histological, laboratory, and imaging studies:
Histopathology: Tissue biopsy (e.g., abdominal fat, bone marrow, or affected organs) with Congo red staining showing apple-green birefringence under polarized light remains the diagnostic gold standard.
Serum and Urine Studies: Serum free light chain (sFLC) assay, combined with immunofixation electrophoresis, achieves a sensitivity of 97–100%. Elevated cardiac biomarkers (troponin, NT-proBNP) aid in diagnosis and prognosis.
Imaging: Echocardiography and cardiac magnetic resonance imaging are critical for assessing cardiac involvement. Advanced techniques such as ¹⁸F-florbetapir PET/CT help differentiate AL from other amyloid types.
Staging and Risk Stratification
The Mayo 2012 staging system, based on cardiac troponin T (≥0.025 µg/L), NT-proBNP (≥1800 ng/L), and the difference between involved and uninvolved free light chains (dFLC ≥180 mg/L), stratifies patients into four prognostic groups. This system guides treatment intensity and predicts survival, emphasizing the central role of cardiac involvement in outcomes.
Evolving Treatment Strategies
The treatment goal is rapid and deep reduction of amyloidogenic light chains to halt or reverse organ damage.
First-Line Therapy: For transplant-eligible patients, bortezomib-based induction followed by autologous stem cell transplantation (ASCT) yields high rates of hematologic response, with complete response (CR) rates reaching 60% post-consolidation. For ineligible patients, daratumumab combined with bortezomib, cyclophosphamide, and dexamethasone (Dara-CyBorD) has become the standard, significantly improving hematologic and organ responses.
Relapsed/Refractory Disease: Options include pomalidomide, ixazomib, and bendamustine, though response rates remain modest. Retreatment with daratumumab-based regimens shows promise. Emerging therapies such as the BCMA-targeting bispecific antibody teclistamab and BCMA-directed CAR-T cell therapy have demonstrated encouraging efficacy in early studies, including deep responses in refractory cases.
Organ-Directed Support: In cases of irreversible organ damage, kidney or heart transplantation may be considered, often combined with subsequent ASCT to prevent disease recurrence.
Prognosis and the Role of Minimal Residual Disease (MRD)
Achieving hematologic CR and organ response correlates with improved survival. The depth of response is increasingly assessed using MRD detection by next-generation flow cytometry. MRD negativity is associated with higher rates of cardiac and renal response, though its impact on overall survival requires further validation.
Future Perspectives
The treatment landscape for AL amyloidosis is rapidly evolving, driven by immunotherapy and precision medicine. Daratumumab-based regimens represent a significant advance, while bispecific antibodies and CAR-T therapies offer new avenues for refractory disease. Future efforts should focus on:
Early diagnosis through increased clinical awareness and sensitive biomarkers.
Personalized treatment based on genetic and molecular profiling.
Large multicenter studies to validate novel therapies and MRD-driven strategies.
Conclusion
AL amyloidosis remains a challenging disease, but significant progress in diagnostic accuracy and therapeutic efficacy has improved patient outcomes. The integration of advanced imaging, biomarker-driven staging, and immunotherapy has transformed management, enabling deeper and more rapid responses. Continued research into the mechanisms of amyloid formation and resistance, along with the development of targeted and cellular therapies, holds promise for further advancing the care of patients with this complex condition.
Full text
http://xiahepublishing.com/2996-3427/OnA-2025-00018
The study was recently published in the Oncology Advances.
Oncology Advances is dedicated to improving the diagnosis and treatment of human malignancies, advancing the understanding of molecular mechanisms underlying oncogenesis, and promoting translation from bench to bedside of oncological sciences. The aim of Oncology Advances is to publish peer-reviewed, high-quality articles in all aspects of translational and clinical studies on human cancers, as well as cutting-edge preclinical and clinical research of novel cancer therapies.
Follow us on X: @xiahepublishing
Follow us on LinkedIn: Xia & He Publishing Inc.
END
Lactate, once considered a metabolic waste product, is now recognized as a key regulator of cellular homeostasis and disease progression. In gynecological malignancies—including ovarian, cervical, and endometrial cancers—lactate accumulation drives a novel post-translational modification known as lactylation. This modification serves as a critical bridge between metabolic reprogramming and epigenetic regulation, promoting tumor proliferation, metastasis, and therapy resistance. Emerging therapeutic strategies targeting lactate production, transport, and lactylation itself show significant anticancer potential, particularly when combined with immunotherapy. This ...
Background and objectives
Emerging evidence implicates immune dysregulation and neuroinflammation in the pathogenesis of epilepsy, yet the causal mechanisms remain unclear. This study aimed to investigate the causal effects of immune cells and inflammatory proteins on epilepsy and evaluate the mediating role of inflammatory proteins.
Methods
This study utilized the largest available genome-wide association study data on immune cell phenotypes and inflammatory proteins as exposures, and epilepsy genome-wide association study data from the FinnGen dataset as outcomes. Five Mendelian randomization (MR) methods were applied within a two-sample MR framework to assess causal effects. Furthermore, ...
About The Study: The results of this cohort study suggest that, for older adults, poor olfaction as assessed by a single smell identification test is associated with a higher coronary heart disease risk.
Corresponding Author: To contact the corresponding author, Honglei Chen, PhD, email chenho19@msu.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoto.2025.3740)
Editor’s Note: Please see the article for additional information, including other authors, author contributions ...
About The Study: The findings of this study suggest that maintaining a moderate level of physical activity of approximately 17 metabolic equivalent task-hours/week (i.e., 5 hours of brisk walking or 2 hours of running each week) over 3 decades was sufficient to achieve optimal benefit in reducing digestive system cancer risk.
Corresponding Author: To contact the corresponding author, Edward L. Giovannucci, MD, ScD, email egiovann@hsph.harvard.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoncol.2025.4185)
Editor’s Note: Please see the article for additional information, ...
About The Study: The findings of this study highlight the persistence of misbeliefs and knowledge gaps about the link between alcohol and cancer among U.S. adults, which may contribute to the continuous increase in alcohol consumption. Individuals who drink alcohol were more likely to believe that alcohol consumption has no effect on cancer risk, which is alarming, given the growing burden of alcohol-related cancers in the U.S.
Corresponding Author: To contact the corresponding author, Sanjay Shete, PhD, email sshete@mdanderson.org.
To access the embargoed study: Visit our For The Media ...
Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and most comprehensive molecular analysis of renal medullary carcinoma (RMC), a rare and aggressive form of kidney cancer, leading to the identification of TROP2 as a promising therapeutic target.
What is the key discovery in this research and why is it significant?
By evaluating 25 patient samples, the researchers identified overexpression of TROP2 and several other cell-surface proteins in RMC, as well as upregulation of the Hippo pathway. These findings led to the exploration of sacituzumab govitecan, a TROP2-targeted antibody-drug ...
Some common hormonal contraceptives are linked to a slightly higher risk of breast cancer than others. This is shown by a new Swedish study from Uppsala University, in which researchers followed more than two million women and teenage girls in Sweden to identify how different hormonal contraceptives affect the risk of breast cancer.
Peer-review / Observational study / Women
In Sweden, hundreds of thousands of women use hormonal contraceptives every year. Over time, new products have been developed – from combined contraceptive pills ...
Stroke is a leading cause of death and disability, affecting 1 in 4 people during their lifetime. Stroke happens when blood vessels in the brain get clogged or damaged, impairing blood flow and oxygen supply to the brain, which leads to death of neurons and other brain cells. Although brain damage can be limited by interventions to restore blood flow, most stroke survivors experience some lifelong impairments of e.g. speech, movement, or cognitive function.
Despite the existence of immature stem cells in the brain, their role in repair is uncertain and the brain’s ...
If cancer is a disease of overabundance, where cells divide without restraint and tumors grow despite the body’s best interests, then degenerative diseases are disorders of deprivation.
When malfunctions occur in the biological machinery our muscles or our brains use for renewal and repairs, these tissues gradually wither. This kind of decline is the hallmark of diseases such as Alzheimer’s disease or Duchenne muscular dystrophy.
Scientists have long sought to develop treatments that enhance the muscle’s self-renewal capabilities ...
More than half of American adults misunderstand or underestimate the link between alcohol consumption and cancer
Alcohol drinkers are especially likely to believe that drinking has no effect on cancer risk
Correcting these misbeliefs may strengthen adherence to U.S. Surgeon General’s alcohol consumption guidelines to lower cancer risk
HOUSTON, OCTOBER 30, 2025 – Despite clear evidence linking alcohol use to increased cancer risks, public awareness of this connection remains low in the U.S., according to new research from The University of Texas MD Anderson ...
